Ozempic for Alzheimer’s? What Drives Brain Age; Primary Care Alzheimer’s Guideline

Two clinical trials investigating semaglutide (Ozempic, Wegovy) as an early Alzheimer’s treatment are expected to wrap up in 2025. (New Scientist)

Researchers say stem cell treatments for Parkinson’s disease or epilepsy may enter the clinic soon. (Nature)

Vascular-related lifestyles and health were associated with brain appearance, with healthier profiles tied to younger-looking brains at age 70. (Alzheimer’s & Dementia)

In phase III studies of episodic or chronic migraine prevention, oral atogepant (Qulipta) showed efficacy and improved functional measures within the first 4 weeks of treatment. (Neurology)

Topline results were positive in the phase II study of investigational CT1812 in people with dementia with Lewy bodies, Cognition Therapeutics said.

The FDA cleared Onward Medical’s ARC-EX non-invasive electrical stimulation device to treat chronic spinal cord injury.

The Alzheimer’s Association issued a clinical practice guideline on evaluating, testing, and counseling about Alzheimer’s disease and dementia in primary care. (Alzheimer’s & Dementia)

A close look at the effects of mutations in C21ORF2, a gene linked with amyotrophic lateral sclerosis (ALS), showed that primary cilia were dysfunctional. (Brain)

Compared with children who played individual sports, those involved in team sports or both types of sports showed superior executive function at ages 10 and 11. (JAMA Network Open)

The New York Times looked at the life of Naomi Feil, MSW (1932-2023), who developed validation therapy to connect with people who had severe dementia.